GRM5 and Parkinson disease: Negative allosteric modulators of mGlu5, and dipraglurant in particular, represent an attractive approach to treat the primary motor symptoms of Parkinson’s disease, concomitant psychiatric non-motor symptoms and dyskinesias induced by long-term L-Dopa treatment.